Severe autoimmune hepatitis in a chronic myeloid leukemia patient treated with interferon alpha and with complete genetic response

✍ Scribed by Steegmann, Juan Luis; Requena, María José; García-Buey, María Luisa; Granados, Enrique; Romero, Rafael; Fernández-Rañada, Jose María; Moreno, Ricardo

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 19 KB
• Volume: 59
• Category: Article
• ISSN: 0361-8609
• DOI: 10.1002/(sici)1096-8652(199809)59:1<95::aid-ajh19>3.0.co;2-0

✦ Synopsis

A patient with chronic myeloid leukemia (CML) treated with interferon alpha (IFN alpha) and who developed autoimmune hepatitis (AIH) is described. The patient was treated with IFN alpha 2a, a complete cytogenetic response was achieved 5 months later, and this response has lasted now more than 7 years. Autoimmune hypothyroidism appeared at 18 months of treatment, and 1 year later severe type I autoimmune hepatitis developed. To our knowledge this is the first report of such complication in an IFN alpha-treated CML patient. Am.